22/07/2025
LONDON, Friday 18 July 2025, Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today welcomes the opening of a new research and development (R&D) facility in Cambridge, UK, by Her Royal Highness The Princess Royal. With the new site focused on synthetic rescue for serious diseases, Insmed expands its UK-based R&D presence in Cambridge.
The state-of-the-art 17,000 sq ft site represents a significant expansion of Insmed’s global R&D capabilities and underscores the company’s commitment to transforming the lives of patients with serious diseases. Located here on Campus, the new facility is focused on pioneering research in synthetic rescue - an innovative approach to identifying new treatment options for conditions with few or no effective therapies.
During the visit, The Princess Royal toured the facility and met with members of the Insmed team, including Chair and CEO Will Lewis and Dr Tom Heightman, SVP of Research. She learned about the company’s groundbreaking work, which integrates advanced molecular biology techniques with human genetic data to restore disrupted biological pathways and potentially correct the impact of gene defects.
Speaking during the visit, Will Lewis said:
“The work we are doing in Cambridge is central to our research and development at Insmed and has the potential to deliver much-needed therapies for patients with serious diseases globally.”
Dr Tom Heightman added:
“Our work in synthetic rescue was developed in Cambridge, and the opening of this site marks an exciting new chapter in our relationship with this region and the broader UK life sciences industry.”
The facility brings together multiple R&D specialities under one roof to support a highly collaborative approach, from target discovery through to translational science. The Cambridge team will also work closely with Insmed’s other sites in the US, reinforcing global collaboration across the organisation.
Insmed’s investment at Babraham Research Campus highlights the Campus’s role as a hub for bioscience innovation and its unique environment for growing life science companies. We are proud to support the continued success of companies like Insmed and to provide a collaborative space where scientific innovation can thrive.